Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6467-6473

  Cullen, Matthew D ^a   Ho, William C ^b   Bauman, Joseph D ^b   Das, Kalyan ^b   Arnold, Eddy ^b   Hartman, Tracy L ^c   Watson, Karen M ^c   Buckheit Jr , Robert W ^c   Pannecouque, Christophe ^d   De Clercq, Erik ^d   Cushman, Mark ^a  

^a PURDUE UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c ImQuest Biosciences   (United States)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKENYLDIARYLMETHANE DERIVATIVE; LYSINE; METHANE; METHYL 5 [1 (3,7 DIMETHYL 2 OXO 2,3 DIHYDROBENZ[D]OXAZOL 5 YL) 5 (5 METHYL 1,3,4 OXADIAZOL 2 YL)PENT 1 ENYL] 2 METHOXY 3 METHYLBENZOTHIOATE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG BINDING; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; HYDROLYSIS; HYDROPHOBICITY; NONHUMAN; RAT;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; METHANE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 70350066155     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901167t     Document Type: Article

References (38)

1. Cheng, Y. C.; Gao, W. Y.; Chen, C. H.; Vazquez-Padua, M.; Starnes, M. C. DNA Polymerases Versus HIV Reverse Transcriptase in AIDS Therapy. Ann. N.Y. Acad. Sci. 1990, 616, 217-223.
2. Jacobo-Molina, A.; Ding, J.; Nanni, R. G.; Clark, A. D., Jr; Lu, X.; Tantillo, C.; Williams, R. L.; Kamer, G.; Ferris, A. L.; Clark, P.; Hizi, A.; Hughes, S. H.; Arnold, E. Crystal Structure of Human Immunodeficiency Virus Type I Reverse Transcriptase Complexed with Double-Stranded DNA at 3.0 Å Resolution Shows Bent DNA. Proc. Nat. Acad. Sci. U.S.A. 1993, 90, 6320-6324. (Pubitemid 23191507)
3. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The Structure of Unliganded Reverse Transcriptase from the Human Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226.
4. Gulick, R. M.; Staszewski, S. New Drugs for HIV Therapy. AIDS 2002, 16, S135-S144.
5. De Clercq, E. New anti-HIV Agents and Targets. Med. Res. Rev. 2002, 22, 531-565.
6. De Clercq, E. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future. Chem. Biodiversity 2004, 1, 44-64.
7. De Clercq, E. New Approaches toward Anti-HIV Chemotherapy. J. Med. Chem. 2005, 48, 1297-1313.
8. Vivet-Boudou, V.; Didierjean, J.; Isel, C.; Marquet, R. Nucleoside and Nucleotide Inhibitors of HIV-1 Replication. Cell. Mol. Life Sci. 2006, 63, 163-186.
9. De Clercq, E. Nucleoside/Nucleotide Inhibitors of HIV Reverse Transcriptase. Infect. Dis. Ther. 2003, 30, 485-504.
10. Tabba, H. D.; Chang, R. S.; Smith, K. M. Isolation, Purification, and Partial Characterization of Prunellin, an Anti-HIV Component from Aqueous Extracts of Prunella vulgaris. Antiviral Res. 1989, 11, 263-274.
11. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Pettibone, D. J.; O'Brien, J. A.; Ball, R. G.; Balani, S. K.; Lin, J. H.; Chen, I.-W.; Schleif, W. A.; Sardana, V. V.; Long, W. J.; Byrnes, V. W.; Emini, E. A. L-743,726 (DMP-266): a Novel, Highly Potent Nonnucleoside Inhibitor of the Human Immunodificiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 1995, 39, 2602-2605.
12. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D.; Hughes, S. H.; Arnold, E. Structure of Unliganded HIV-1 Reverse Transcriptase at 2.7 Angstrom Resolution: Implications of Conformational Changes for Polymerization and Inhibition Mechanisms. Structure 1996, 4, 853-860. (Pubitemid 26312368)
13. Eshleman, S. H.; Jackson, J. B. Nevirapine Resistance After Single Dose Prophylaxis. AIDS Rev. 2002, 4, 59-63.
14. Cushman, M.; Golebiewski, M.; Buckheit, R. W., Jr.; Graham, L.; Rice, W. G. Synthesis and Biological Evaluation of an Alkenyldiarylmethane (ADAM) which Acts as a Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor. Bioorg. Med. Chem. Lett. 1995, 5, 2713-2716.
15. Cushman, M.; Casimiro-Garcia, A.; Williamson, K.; Rice, W. G. Synthesis of a Non-Nucleoside Reverse Transcriptase Inhibitor in the Alkenyldiarylmethane (ADAM) Series with Optimized Potency and Therapeutic Index. Bioorg. Med. Chem. Lett. 1998, 8, 195-198.
16. Casimiro-Garcia, A.; Micklatcher, M.; Turpin, J. A.; Stup, T. L.; Watson, K.; Buckheit, R. W., Jr.; Cushman, M. Novel Modifications in the Alkenyldiarylmethane(ADAM)Series of Non-Nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 1999, 42, 4861-4874.
17. Xu, G.; Micklatcher, M.; Silvestri, M.; Hartman, T. L.; Burrier, J.; Osterling, M. C.; Wargo, H.; Turpin, J. A.; Buckheit, R. W., Jr.; Cushman,M. The Biological Effects of Structural Variation at the Meta Position of the Aromatic Rings and at the End of the Alkenyl Chain in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 2001, 44, 4092-4113.
18. Silvestri, M. A.; Nagarajan, M.; De Clercq, E.; Pannecouque, C.; Cushman, M. Design, Synthesis, Anti-HIV Activities, and Metabolic Stabilities of Alkenyldiarylmethane (ADAM) Non-nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 2004, 47, 3149-3162.
19. Deng, B. L.; Cullen, M. D.; Zhou, Z. G.; Hartman, T. L.; Buckheit, R. W.; Pannecouque, C.; De Clercq, E.; Fanwick, P. E.; Cushman, M. Synthesis and Anti-HIV Activity ofNewAlkenyldiarylmethane (ADAM) Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Incorporating Benzoxazolone and Benzisoxazole Rings. Bioorg. Med. Chem. 2006, 14, 2366-2374.
20. Cullen, M. D.; Deng, B. L.; Hartman, T. L.; Watson, K. M.; Buckheit, R. W.; Pannecouque, C.; De Clercq, E.; Cushman, M. Synthesis and Biological Evaluation of Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors that Possess Increased Hydrolytic Stability. J. Med. Chem. 2007, 50, 4854-4867.
21. Schäfer, W.; Friebe, W.-G.; Leinert, W.; Mertens, A.; Poll, T.; von der Saal, W.; Zilch, H.; Nuber, H.; Ziegler, M. L. Non-Nucleoside Inhibitors of HIV-1Reverse Transcriptase:MolecularModeling and X-ray Structure Investigations. J. Med. Chem. 1993, 36, 726-732.
22. Das, K.; Clark, A. D.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Bethune, M. P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective Against Wild-Type and Drug-Resistant HIV-1 Variants. J. Med. Chem. 2004, 47, 2550-2560.
23. Das, K.; Lewi, P. L.; Hughes, S. H.; Arnold, E. Crystallography and the Design of Anti-AIDS Drugs: Conformational Flexibility and Positional Adaptability are Important in the Design of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Prog. Biophys. Mol. Biol. 2005, 88, 209-231.
24. Cushman, M.; Golebiewski, W. M.; Graham, L.; Turpin, J. A.; Rice, W. G.; Fliakas-Boltz, V.; Buckheit, R. W., Jr. Synthesis and Biological Evaluation of Certain Alkenyldiarylmethanes as Anti-HIV-1 Agents Which Act as Non-Nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 1996, 39, 3217-3227.
25. Xu, G.; Loftus, T. L.; Wargo, H.; Turpin, J. A.; Buckheit, R. W.; Cushman, M. Solid-Phase Synthesis of the Alkenyldiarylmethane (ADAM) Series of Non-Nucleoside Reverse Transcriptase Inhibitors. J. Org. Chem. 2001, 66, 5958-5964.
26. Silvestri, M. A.; Nagarajan, M.; De Clercq, E.; Pannecouque, C.; Cushman, M. Design, Synthesis, Anti-HIV Activities, and Metabolic Stabilities of Alkenyldiarylmethane (ADAM) Non-nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 2004, 47, 3149-3162.
27. Das, K.; Bauman, J. D.; Clark, A. D.; Frenkel, Y. V.; Lewi, P. J.; Shatkin, A. J.; Hughes, S. H.; Arnold, E. High-Resolution Structures of HIV-1 Reverse Transcriptase/TMC278 Complexes: Strategic Flexibility Explains Potency against Resistance Mutations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1466-1471.
28. Himmel, D. M.; Das, K.; Clark, A. D.; Hughes, S. H.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.; Grierson, D. S.; Arnold, E. Crystal Structures for HIV-1 Reverse Transcriptase in Complexes with Three Pyridinone Derivatives: A New Class of Non-Nucleoside Inhibitors Effective against a Broad Range of Drug-Resistant Strains. J. Med. Chem. 2005, 48, 7582-7591.
29. Jacques, P. S.; Wohrl, B. M.; Ottmann, M.; Darlix, J. L.; Legrice, S. F. J. Mutating the Primer Grip of P66 Hiv-1 Reverse-Transcriptase Implicates Tryptophan-229 in Template-Primer Utilization. J. Biol. Chem. 1994, 269, 26472-26478.
30. Ghosh, M.; Jacques, P. S.; Rodgers, D. W.; Ottman, M.; Darlix, J. L.; leGrice, S. F. J. Alterations to the Primer Grip of p66 HIV-1 Reverse Transcriptase and Their Consequences for Template-Primer Utilization. Biochemistry 1996, 35, 8553-8562.
31. Pelemans, H.; Esnouf, R.; De Clercq, E.; Balzarini, J. Mutational Analysis of Trp-229 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Identifies this Amino Acid Residue as a Prime Target for the Rational Design of New Non-Nucleoside RT Inhibitors. Mol. Pharmacol. 2000, 57, 954-960.
32. Bauman, J. D.; Das, K.; Ho, W. C.; Baweja, M.; Himmel, D. M.; Clark, A. D.; Oren, D. A.; Boyer, P. L.; Hughes, S. H.; Shatkin, A. J.; Arnold, E. Crystal Engineering of HIV-1 Reverse Transcriptase for Structure-Based Drug Design. Nucleic Acids Res. 2008, 36, 5083-5092.
33. Otwinowski, Z.; Minor, Z. Processing of X-Ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
34. Vagin, A.; Teplyakov, A. MOLREP: an Automated Program for Molecular Replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
35. Emsley, P.; Cowtan, K. Coot: Model-Building Tools for Molecular Graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
36. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921.
37. Rice, W. G.; Bader, J. P. Discovery and In Vitro Development of AIDS Antiviral Drugs as Biopharmaceuticals. Adv. Pharmacol. (San Diego) 1995, 33, 389-438.
38. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and Automated Tetrazolium-based Colorimetric Assay for Detection of Anti-HIV Compounds. J. Virol. Methods 1988, 20, 309-321.